Restless Legs Syndrome

Confirm all core features in the history: an urge to move the legs, usually with uncomfortable sensations; onset or worsening during rest or inactivity; partial or complete relief with movement; and predominant evening or nighttime symptoms. RLS is a circadian sensorimotor disorder, and diagnosis is based on International Restless Legs Syndrome Study Group clinical criteria rather than polysomnography. ScienceDirect+1ScienceDirectTreatment of Restless Legs Syndrome - ScienceDirectScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatment - ScienceDirect

Ask the patient to describe what happens during immobility and what changes after walking or stretching. Nocturnal periodic limb movements support a coexisting sleep-related movement phenomenon but do not establish RLS; periodic limb movements in sleep occur in approximately 80% of patients with RLS. If sleep disruption, another sleep disorder, or periodic limb movement burden will change management, polysomnography can document sleep disturbance and limb movements. Nature+1NatureHepcidin and ferritin levels in restless legs syndrome: a case–control study | Scientific ReportsNeurologyRestless legs syndrome

Do not label involuntary nocturnal jerks as RLS without a conscious urge to move and movement-related relief. In Parkinson disease, distinguish RLS from periodic limb movements and diphasic dyskinesia before assigning treatment; these entities can overlap clinically but require different management. NatureNaturePeriodic limb movements in Parkinson's disease: a critical ...

Obtain serum ferritin as part of the baseline evaluation of clinically meaningful RLS. Low iron stores are a recognized treatment target, and a ferritin threshold of 75 micrograms/L or lower has been used to direct iron supplementation in an RLS/PLM treatment algorithm. Nature+2NaturePeriodic limb movements in Parkinson's disease: a critical ...ScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatmentPubMedRestless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC

Medication reconciliation should specifically identify dopamine antagonists, selected antidepressants, and antihistamines, which can worsen RLS symptoms; assess alcohol, caffeine, and nicotine exposure as potentially modifiable aggravators. When a suspected medication is necessary, balance symptom burden against the indication for that agent rather than stopping it reflexively. The Lancet+1The LancetInitiation and termination of dialysis in older patients with ...ScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatment

Check for renal impairment before prescribing gabapentin, gabapentin enacarbil, or pregabalin because reduced renal clearance can produce accumulation. In chronic renal insufficiency, begin at the lower end of dosing and titrate toward a lower target dose. PubMedPubMedRestless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC

For low iron stores, use iron replacement as a first-line intervention. Oral iron is appropriate when tolerated; intravenous iron is an option for oral intolerance and for intense, severe, refractory symptoms or augmentation. Vitamin C improves oral iron absorption, while gastrointestinal upset, nausea, and constipation are common oral-iron limitations. ScienceDirect+1ScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatmentPubMedRestless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC

For troublesome persistent RLS requiring medication, select an alpha-2-delta ligand such as gabapentin, gabapentin enacarbil, or pregabalin when the goal is to avoid dopaminergic augmentation and impulse-control toxicity. Gabapentin enacarbil is FDA approved for RLS; gabapentin and pregabalin have demonstrated efficacy but are not identified as FDA-approved RLS therapies in the comparative review. ScienceDirect+1ScienceDirectTreatment of Restless Legs Syndrome - ScienceDirectPubMedExecutive Summary - Treatment for Restless Legs Syndrome - NCBI Bookshelf

Counsel patients receiving alpha-2-delta ligands about sleepiness, dizziness, unsteadiness, possible driving impairment, and fall risk, particularly in older adults. Peripheral edema and weight gain may occur with gabapentin. Dose conservatively in renal impairment. PubMedPubMedRestless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC

Dopamine agonists—pramipexole, ropinirole, and rotigotine—are effective and FDA approved for RLS, but reserve long-term use for situations in which anticipated benefit outweighs augmentation and impulse-control risk. Keep the dose as low as possible and do not exceed RLS-specific recommended doses. ScienceDirect+2ScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatmentScienceDirectTreatment of Restless Legs Syndrome - ScienceDirectPubMedExecutive Summary - Treatment for Restless Legs Syndrome - NCBI Bookshelf

Levodopa can relieve RLS but chronic use is frequently associated with augmentation. Opioids may be considered as an alternative in severe disease, particularly after dopamine agonist-related augmentation, while the evidence base for opioids and clonazepam is less sufficient for routine recommendation. ScienceDirect+1ScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatmentScienceDirectTreatment of Restless Legs Syndrome - ScienceDirect

At every follow-up after starting levodopa or a dopamine agonist, ask whether symptoms now begin earlier in the day, emerge more quickly with inactivity, have become more intense, or have spread beyond the legs. This cluster defines augmentation and differs from ordinary residual symptoms. ScienceDirect+2ScienceDirectTreatment of Restless Legs Syndrome - ScienceDirectPubMedExecutive Summary - Treatment for Restless Legs Syndrome - NCBI BookshelfPubMedRestless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC

High dopaminergic dose is a modifiable augmentation risk factor. When augmentation emerges, first address low iron stores and extrinsic exacerbators, including antidepressants and antihistamines when appropriate; alpha-2-delta therapy and, in selected severe cases, opioids are alternatives to continued dopaminergic escalation. ScienceDirect+1ScienceDirectRestless legs syndrome: clinical presentation diagnosis and treatmentScienceDirectAssociation of low serum ferritin levels with augmentation in patients with restless legs syndrome: A systematic review and meta-analysis

Screen specifically for impulse-control behaviors during dopamine agonist therapy. Comparative evidence estimates impulse-control disorders in up to 9%-17% of patients with RLS receiving these drugs, making anticipatory counseling and active surveillance clinically necessary. PubMedPubMedExecutive Summary - Treatment for Restless Legs Syndrome - NCBI Bookshelf

In older adults, alpha-2-delta ligand selection requires explicit assessment of baseline gait stability, fall risk, and driving demands because sleepiness, dizziness, and unsteadiness are common adverse effects. Renal impairment increases exposure, so lower starting doses and lower targets are advised. PubMedPubMedRestless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC

In children and adolescents, use pediatric RLS diagnostic criteria and pediatric-focused iron-treatment guidance rather than extrapolating adult pharmacotherapy strategies. Pediatric RLS criteria and an International Restless Legs Syndrome Study Group iron-treatment guideline are specifically cited in contemporary pediatric sleep medicine references. Wolters Kluwer+1Wolters KluwerSleep-Wake Disorders in ChildhoodWolters KluwerSleep Disorders in Childhood | Continuum

For Parkinson disease with suspected nocturnal limb movements, first separate RLS, periodic limb movements, and diphasic dyskinesia. In the cited Parkinson disease algorithm, a periodic limb movement index of at least 15 prompts ferritin assessment, with ferritin 75 micrograms/L or lower directing iron plus dopaminergic therapy; this is a Parkinson disease-specific framework. NatureNaturePeriodic limb movements in Parkinson's disease: a critical ...